SalubrisBio
Corporate Round in 2024
SalubrisBio is a clinical-stage biotechnology company dedicated to discovering and developing novel antibody and protein-based therapeutics.
Precision Scientific
Venture Round in 2023
Precision Scientific offers drug mechanism research services to pharmaceutical and biotechnology companies. Utilizing its proprietary AI technology ALBERT, the company employs machine learning algorithms on multi-omics data to deliver solutions in oncology research, including drug target discovery, biomarker identification, indication selection, drug resistance evaluation, and combo therapy strategy.
SalubrisBio
Corporate Round in 2023
SalubrisBio is a clinical-stage biotechnology company dedicated to discovering and developing novel antibody and protein-based therapeutics.
Core Medical Technology
Series C in 2022
Core Medical Technology is a technology enterprise mainly engaged in the research, production, development, and sales of implantable left ventricular assist devices, extracorporeal ventricular assist devices, percutaneous interventional ventricular assist devices, and equipment.
The company was founded in 2016 and is based in Shenzhen, China.
SalubrisBio
Corporate Round in 2022
SalubrisBio is a clinical-stage biotechnology company dedicated to discovering and developing novel antibody and protein-based therapeutics.
Mercator MedSystems
Series D in 2019
Mercator MedSystems develops catheter-guided microfluid injection systems for site-specific delivery of therapeutic agents directly across various blood vessels. Its products include Cricket and Bullfrog micro-infusion catheters, designed to inject therapeutic agents directly into deep tissues without systemic delivery. The company's technology enables targeted treatments for vascular diseases, oncology, and regenerative medicine.
Viracta Therapeutics
Corporate Round in 2018
Viracta Therapeutics, Inc. is a clinical-stage drug development company based in Cardiff, California, that specializes in precision oncology focused on virus-associated malignancies. The company utilizes a viral activation therapy platform to develop treatments for cancers linked to the Epstein-Barr Virus (EBV) and other virus-related diseases. Its lead investigational drug, nanatinostat, is being evaluated in combination with the antiviral valganciclovir as a potential oral therapy for EBV-positive lymphoma, including post-transplant lymphoproliferative disorder, plasmablastic lymphoma, and angioimmunoblastic T cell lymphoma. Viracta is also exploring the application of this approach to other EBV-associated conditions, such as nasopharyngeal carcinoma and gastric carcinoma. Founded in 2007 and rebranded from HemaQuest Pharmaceuticals in 2015, Viracta Therapeutics is actively conducting multiple clinical trials to advance its therapeutic candidates.
KingstronBio
Series B in 2018
KingstronBio specializes in the development and manufacturing of advanced heart valve products for cardiac surgeries. The company focuses on creating a comprehensive range of biological heart valves and annuloplasty rings that are designed to be minimally invasive. Utilizing cutting-edge technologies, including anti-calcification and leaflet thinning methods, KingstronBio aims to provide innovative solutions that enhance patient outcomes and improve the overall effectiveness of cardiac procedures.
Jinjiang Electronic Technology
Corporate Round in 2018
Jinjiang Electronic Technology is a med-tech company focused on the research and development as well as the manufacture of advanced medical equipment designed to enhance patient care in the field of cardiac electrophysiology. The company offers a range of innovative products, including a 3D cardiac mapping system, electrophysiology recording system, cardiac RF ablation generator, and irrigation pump. These devices provide comprehensive solutions aimed at diagnosing and treating arrhythmias, ultimately improving the quality of life for patients with heart conditions.
GO Therapeutics
Funding Round in 2017
GO Therapeutics specializes in developing tumor-specific antibodies for cancer immunotherapies. Its innovative approach combines protein expression with aberrant glycosylation patterns to enhance tumor specificity, minimizing harm to healthy tissues.
Zhongke Jiankang Wang
Angel Round in 2016
Zhongke Health Industry Group is a manufacturer of health care products. It provides goods for managing blood sugar, nourishing and guarding the liver, combating fatigue, and maintaining cardiovascular and cerebrovascular health. Their products include spore powder capsules, bovine colostrum capsules, and Ganoderma lucidum spore oil.